Mitochondria are becoming an increasingly important target for the development of novel drugs for tumors. The role of mitochondria in regulating anti-tumor immunity has been widely explored recently. Mitochondria contains plenty of structural molecules (e.g. mitochondrial DNA (mtDNA)) and metabolic products (e.g. reactive oxygen species (ROS) and adenosine triphosphate (ATP)), which could act as damage-associated molecular patterns (DAMPs) and stimulate the immune system when extensively released into the cytosol or extracellular space through binding to and activating pattern recognition receptors (PRRs). In addition, alterations in the mitochondrial metabolism may alter the functions of immune cells and remodel the tumor microenvironment (TME).
Harnessing the intrinsic immunity of individuals is essential for cancer treatment, which makes immunotherapy one of the most commonly used strategies currently. However, cancer cells have evolved different mechanisms to escape from host immunity, resulting in immune resistance and compromising therapeutic efficacy. Over the years, targeting mitochondria has been recognized as holding great potential to break immune tolerance to currently available anticancer treatments and improve patient outcomes in the end, and anticancer treatment strategies based on targeting mitochondria to modulate antitumor immunity, including chemotherapy and radiotherapy, have also been reported. Unraveling the underlying mechanisms of mitochondria in regulating anti-tumor immunity and promoting the translation of mitochondria-targeting strategies into clinic is of paramount importance for the advancement of cancer therapeutics.
This research topic aims to provide an overview of the state-of-the-art advances in the exploration of mitochondria in the regulation of anti-tumor immunity. Original Research articles, Review articles and Perspective articles by experts in the field are welcome, including but not limited to the following contents:
? Molecular mechanisms in the involvement of mitochondria in regulating anti-tumor immunity, including both in cancer cells and immune cells
? Novel cancer treatment strategies targeting mitochondria to reshape anti-tumor immunity both as monotherapy and combined therapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Mitochondria are becoming an increasingly important target for the development of novel drugs for tumors. The role of mitochondria in regulating anti-tumor immunity has been widely explored recently. Mitochondria contains plenty of structural molecules (e.g. mitochondrial DNA (mtDNA)) and metabolic products (e.g. reactive oxygen species (ROS) and adenosine triphosphate (ATP)), which could act as damage-associated molecular patterns (DAMPs) and stimulate the immune system when extensively released into the cytosol or extracellular space through binding to and activating pattern recognition receptors (PRRs). In addition, alterations in the mitochondrial metabolism may alter the functions of immune cells and remodel the tumor microenvironment (TME).
Harnessing the intrinsic immunity of individuals is essential for cancer treatment, which makes immunotherapy one of the most commonly used strategies currently. However, cancer cells have evolved different mechanisms to escape from host immunity, resulting in immune resistance and compromising therapeutic efficacy. Over the years, targeting mitochondria has been recognized as holding great potential to break immune tolerance to currently available anticancer treatments and improve patient outcomes in the end, and anticancer treatment strategies based on targeting mitochondria to modulate antitumor immunity, including chemotherapy and radiotherapy, have also been reported. Unraveling the underlying mechanisms of mitochondria in regulating anti-tumor immunity and promoting the translation of mitochondria-targeting strategies into clinic is of paramount importance for the advancement of cancer therapeutics.
This research topic aims to provide an overview of the state-of-the-art advances in the exploration of mitochondria in the regulation of anti-tumor immunity. Original Research articles, Review articles and Perspective articles by experts in the field are welcome, including but not limited to the following contents:
? Molecular mechanisms in the involvement of mitochondria in regulating anti-tumor immunity, including both in cancer cells and immune cells
? Novel cancer treatment strategies targeting mitochondria to reshape anti-tumor immunity both as monotherapy and combined therapy
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.